Activity of 2-[3-(2-chloroethyl)-3-nitrosoureido]-1,3-propandyоl (chlonisol) versus lomustine in intracranial transplanted tumor model in mice

Background. Alkylating drugs have been used in tumor chemo therapy for many decades, and the search for effective compounds continues.

The aim of the study was to study the activity of the developed new compound – 2-[3-(2-chloroethyl)-3-nitrosoureido]-1,3-propanediol (chlonisol) in comparison with lomustine (CCNU) from the nitrosoalkylurea group, which is similar in chemical structure, in the model of intracranially transplanted Ehrlich's tumor and sarcoma 180 in mice.

Methods. According to the developed technique, 64 female mice of the BALB/c line were punctured in the skull under anesthesia and inoculated with tumor cells of Ehrlich's carcinoma or sarcoma 180 in 0.9 % sodium chloride solution. After 24 hours, the test substances were administered at the maximum tolerated doses – chlonisol (20 mg/kg, i.p.) and lomustine (50 mg/kg, orally), once. The effect was compared with the control (solvent injection).

Results. Chlonisol significantly increased the median overall survival (MOS) of animals after intracranial transplantation of both Ehrlich's tumor (by 39 %) and sarcoma 180 (by 84 %) compared with control (p<0.0001). Chlonisol reduced the risk of death in mice by 73 % compared to control in Ehrlich tumor transplantation and by 83 % in sarcoma 180 (p<0.0001). In contrast, lomustine did not show a significant therapeutic effect in intracranial transplantation of both tumors.

Conclusion. The high activity of chlonisol in comparison with lomustine gives reason to consider it as a potential cytostatic agent in the treatment of nervous system tumors.

1. Ostrovskaya LA, Filov VA, Ivin BA, et al. Chlonizol – the new alkylnitrosourea drug with antitumor activity. Russian biotherapeutic journal. 1998;3(1):37–48. (In Russ).].

2. Stukov AN, Esikov KA, Usmanova LM, et al. Synthesis and antitumor activity of 2-[3-(2-chloroethy)-3-nitrosoureido] -1,3-propanediol (chlonisol). Pharmaceutical Chemistry Journal. 2020;54(6):579–581. DOI: 10.1007/ s11094-020-02242-7

3. Stukov AN, Vershinina SF, Kharitonova NN, et al. Domestic antitumor compound 2-[3-(2-chloroethyl)-3-nitrosoureido]-1,3-propanediol (chlonisol). Acute toxicity. Toxicological Review. 2020;6(165):49-53. (In Russ).]. DOI: 10.36946/0869-7922-2020-6-49-53

4. Nikolova T, Roos WP, Krämer OH, et al. Chloroethylating nitrosoureas in cancer therapy: DNA damage, repair and cell death signaling. Biochim Biophys Acta Rev Cancer. 2017; 1868(1):29–39. DOI: 10.1016/j.bbcan.2017.01.004

5. Naskhletashvili DR, Banov SM, Bekyashev AKh, et al. Practical guidelines for drug treatment of metastatic brain tumors. In book: Malignant Tumors: RUSSCO Practice Guidelines No. 3s2, 2020 (vol. 10).08. (In Russ).].

6. Weller M, Le Rhun E. How did lomustine become standard of care in recurrent glioblastoma? Cancer Treat Rev. 2020;87:102029. DOI: 10.1016/j.ctrv.2020.102029.

7. Cruz-Muñoz W, Kerbel RS. Preclinical approaches to study the biology and treatment of brain metastases. Semin Cancer Biol. 2011;21(2):123–130. DOI: 10.1016/j.semcancer.2010.12.001.

8. Murazov IaG, Stukov AN, Zmitrichenko IuG, Niuganen AO, Tochilnikov GV, Latipova DH, Filatova LV, Semiglazova TYu. Evaluation of the antitumor activity of 2-[3-(2-chloroethyl)-3-nitrosoureido]-1,3-propanediol (chlonisol) in C57BL/6 mice with intracranially transplanted B16 melanoma. Farmakokinetika i farmakodinamika. 2021;(1):23–29. (In Russ).].

9. Stukov AN, Filatova LV, Latipova DKh et al. Therapeutic activity of gemcitabine in intracranial tumors. Voprosy onkologii. 2015;61(2):274–279. (In Russ).].

10. Stukov AN, Vershinina SF, Koziavin NA, Semiglazova TYu, Filatova LV, Latipova DKh., Ivantsov AO, Bespalov VG., Semenov AL., Belyaeva OA, Kireeva GS, Alexandrov VA, Tochilnikov GV, Vasilyeva IN, Maydin MA, Tyndyk ML, Kruglov SS, Yanus GA, Yurova MN. Study of the effect of lomustin on HER2-positive breast cancer in FVB/N HER-2 transgenic mice. Siberian Journal of Oncology. 2019;18(5):54–60. (In Russ).]. DOI: 10.21294/1814-4861-2019-18-5-54-60

11. Lee FY, Workman P, Roberts JT, Bleehen NM. Clinical pharmacokinetics of oral CCNU (lomustine). Cancer Chemother Pharmacol. 1985;14(2):125–131. DOI: 10.1007/bf00434350